This was the stock's second consecutive day of losses.

With rates going higher, you have to wonder if AbbVie's worth the risk, even as it's among the safest, if not the safest stock in the group, because of these amazing franchises.

Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading today, for the July 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options ...

With rates going higher, you have to wonder if AbbVie’s worth the risk, even as it’s among the safest, if not the safest stock in the group, because of these amazing franchises. I think it ...

AbbVie (ABBV) stock was on the move after the pharmaceutical company announced the approval of a new cancer drug. The drug, EMRELIS, received accelerated approval from the Food and Drug ...

ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 87% based on the firm’s underlying fundamentals and the stock’s valuation.

Despite these promising developments, AbbVie's stock price remained flat over the past month, contrasting with the broader market, which witnessed notable gains. This apparent stability in the ...

Because of today's vicious bond market-inspired selloff, this fine stock's down a quick 10 points today or more than 5%, but it only yields 3.7%. With rates going higher, you have to wonder if ...

Over the twelve months to March 2025, AbbVie recorded an accrual ratio of -0.17. That implies it has very good cash conversion, and that its earnings in the last year actually significantly understate ...